BioSpace News Archive

Business

Amgen Makes Early $2B Play to Boost ADC Portfolio

In another early high-value deal, Amgen inked a licensing agreement with Synaffix for the development of next-generation antibody-drug conjugates.

January 6, 2023
·
2 min read
·
Tristan Manalac
Business

Fate Ends Potential $3B Janssen Partnership

Thursday, Fate Therapeutics announced it terminated the 2020 collaboration agreement with Johnson & Johnson’s biopharma subsidiary Janssen.

January 6, 2023
·
1 min read
·
George Budwell
JPM Day 1: Highlights

Stay on top of what’s happening at JPM. BioSpace is covering all the key announcements all week.

January 6, 2023
·
7 min read
·
BioSpace Staff
Drug Development

Graphite Bio Shares Tank as Groundbreaking SCD Trial Voluntarily Paused (Updated)

Graphite Bio announced it is voluntarily pausing the Phase I/II study of its lead candidate nula-cel in sickle cell disease.

January 6, 2023
·
2 min read
·
Heather McKenzie
Genetown

Intellia Pushes NTLA-2001 Gene Editing Therapy to the Fore of Near-Term Priorities

Intellia Therapeutics released its strategic priorities for 2023-2024 Thursday, with a heavy emphasis on advancing its lead asset NTLA-2001 as a potential functional cure therapy for ATTR amyloidosis.

January 6, 2023
·
2 min read
·
Lisa Munger
How to Prepare and Protect Your Finances Before Starting a New Job

Starting a new job often comes with a laundry list of tasks. Learn how to prepare and protect your finances before starting a new job, including what to do about your 401k, stocks, health insurance and more.

January 6, 2023
·
3 min read
·
Franklin Carpenter
Policy

FDA Approves Second Alzheimer’s Treatment in Two Years (Updated)

The FDA approved Eisai and Biogen’s lecanemab (Leqembi) Friday afternoon. It is the second anti-amyloid antibody to be approved for Alzheimer’s disease in two years.

January 6, 2023
·
4 min read
·
Heather McKenzie
Business

Moderna Leans into Oncology with CytomX Deal Worth up to $1.2B

Moderna and CytomX ink a cancer partnership.

January 6, 2023
·
2 min read
·
Tristan Manalac
Drug Development

atai’s Ketamine-Based Depression Candidate Falls Short in Phase II

PCN-101, a ketamine-based candidate for treatment-resistant depression being developed by Atai’s Perception Neuroscience, fell short in a Phase II trial.

January 6, 2023
·
1 min read
·
Rosemary Scott
IRLAB to Present at the 6th Neuroscience Innovation Forum in San Francisco on January 8, 2023

IRLAB Therapeutics AB, a company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, announced that the company will participate in the 6th Neuroscience Innovation Forum hosted by Sachs Associates.

January 6, 2023
·
2 min read